Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALVO
ALVOTECH
NASDAQ
$5.38
▲ UP 0.75% (0.04)

KEY STATISTICS

Market Cap$1.82 B
52w High$9.25
52w Low$2.94
Dividend Yield—
Frequency—
P/E-15.82
Volume672.46K
Shares Out.338.22M

COMPANY

LEADERSHIP

Lisa Graver
CHIEF EXECUTIVE
Lisa Graver

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 16, 2022
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
1,279

PRICE TARGET

Target High$10.00
Target Low$5.00
Target Median$10.00
Target Consensus$8.60

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$136.78M
NOV
11
WED

PRICE

$5.38 ▲ UP 0.75% (+$0.04)
$5.33$5.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.38

About Alvotech

https://www.alvotech.com ↗

Alvotech develops and manufactures global biosimilar medicines for autoimmune, eye, bone, and cancer conditions, with key products like AVT02 (Humira biosimilar) and others in various development stages.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT ALVOTECH IS KNOWN FOR

Gobivaz® (golimumab), biosimilar to Simponi®
Gobivaz® (golimumab), biosimilar to Simponi®

Gobivaz® is Alvotech's first-in-market biosimilar to Simponi® (golimumab), used to treat inflammatory conditions, with launches underway in Europe as of late 2025.

COMPETITORS

COMPETITOR
AMGN COMPARE
CHRS COMPARE
PFE COMPARE
TEVA COMPARE
VTRS COMPARE

Revenue by Products

IconPRODUCTFY2023
Humira$12.2B

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
Europe$39.43M $63.51M ▲$157.59M ▲$307.22M ▲
UNITED STATES— — $273.04M $241.37M ▼
Rest of the World— — $59.06M $37.73M ▼
North America$30.78M $18.31M ▼— —
Asia And Other— $9.62M — —
Asia$6.8M — — —
Other Geographical Area$6.02M — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
29
LISTED HERE
8
RANKED BY POSITION SIZE
VXUS
0.00% · 1.7M
IBB
0.05% · 1.0M
SCHE
0.01% · 133.3K
ONEQ
0.01% · 132.1K
PRFZ
0.01% · 73.3K
GLCR
6.18% · 17.3K
BIB
0.06% · 11.2K
EMGM.L
0.00% · 102

INSTITUTIONAL OWNERSHIP

SHARES OWNED
5.23%
HOLDERS
82
TOP 12 OF 82 · RANKED BY POSITION SIZE
Vanguard Group Inc
4.5M sh · $22.56M
Bracebridge Capital, LLC
2.7M sh · $9.28M
Millennium Management LLC
2.1M sh · $7.28M
Oaktree Capital Management LP
1.6M sh · $12.81M
Price T Rowe Associates Inc /Md/
1.5M sh · $11.91M
Littlejohn & Co LLC
1.3M sh · $4.52M
Blackrock, Inc.
1.2M sh · $4.27M
Pointstate Capital LP
1.0M sh · $8.59M
Legal & General Group Plc
581.6K sh · $2.92M
Jpmorgan Chase & Co
504.2K sh · $1.66M
Geode Capital Management, LLC
324.2K sh · $1.11M
Ubs Group AG
322.2K sh · $1.1M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
UNDERWEIGHT 1
BUY 1
HOLD 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Barclays UNDERWEIGHT UBS BUY Deutsche Bank HOLD Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
BHVN$16.03COMPARE
UFPT$287.61COMPARE
PGNY$26.69COMPARE
PAHC$38.43COMPARE
HROW$38.51COMPARE
AMPH$23.76COMPARE
COLL$23.91COMPARE
EVO$1.89COMPARE